ClinicalTrials.gg
CompletedNCT02308007SMART GIVESUpdated Aug 4, 2020Results posted

Multi-Center Study of New Medications to Treat Vaginal Infections

A Phase 3 interventional study of Terconazole and Metronidazole in Vaginal Infection, sponsored by Curatek Pharmaceuticals, LLC. Completed at 51 sites in United States. Open to female participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-08-04.

Sponsored by Curatek Pharmaceuticals, LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
475
Allocation
Randomized
Ages
12 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Vaginitis with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Vaginitis · United States.

Enrollment
6th of 33
475 · median 77
Started
2015
with 4 others
Phase 3
8 of 38
none open now
Registered
17th of 38
by date
Lead sponsor
3 of 38
Curatek Pharmaceuticals, LLC

Among the 38 studies in Vaginitis with a site in United States, this one is the 6th largest by enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2015, is one of 8 in phase 3, and was the 17th registered.

Vaginitis

98 studies on the registry are indexed under Vaginitis; 12 are open to participants now.

Browse Vaginitis studies →

Open to participants now

4 of the 38 studies in Vaginitis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Vaginitis studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 12 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Vaginitis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of terconazole/metronidazole gel in the treatment of vaginal infections

03

Conditions studied

  • Vaginal Infection

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A clinical diagnosis of vaginal infection that is confirmed by laboratory testing and:
  • Capable of providing written or assent
  • Currently not menstruating and not anticipating menses during treatment
  • If heterosexually active, subject must be for ≥ 1 year, surgically sterile, or practicing an acceptable form of
  • Negative pregnancy test
  • Other criteria as identified in the protocol

Exclusion criteria

Exclusion Criteria:

  • Other infectious causes of vulvovaginitis
  • Subject has recently used, or is expected to require the concomitant use of prohibited medications/products
  • Nursing mother
  • Use of any drug within 30 days of enrollment
  • History of to any ingredient/component of the formulations
  • Other criteria as identified in the protocol
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
475 participants (actual)

Study arms

  • Active comparator
    Terconazole vaginal gel

    One applicator full at bedtime

    Drug: Terconazole

  • Active comparator
    Metronidazole vaginal gel

    One applicator full at bedtime

    Drug: Metronidazole

  • Active comparator
    Terconazole/metronidazole vaginal gel

    One applicator full at bedtime

    Drug: Terconazole/metronidazole

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Cure of Mixed Infection (BV and VVC) as Assessed by the Investigator at the Test-of-cure Visit

    The percentage of participants with clinical cure of both bacterial vaginosis (BV) AND vulvovaginal candidiasis (VVC) was compared between the combination therapy and the two single entity treatments. Clinical cure of BV is defined as: discharge has returned to normal/physiologic, negative whiff test, and saline wet mount is \<20% clue cells. Clinical cure of VVC is defined as resolution of all signs and symptoms attributable to vulvovaginal candidiasis

    Time frame: 7-14 days after beginning treatment

Secondary outcomes

  1. Cure of the BV Component of Mixed Infection

    The percentage of participants with both BV and VVC who had clinical cure of bacterial vaginosis (BV) was compared between the combination therapy and the two single entity treatments. Clinical cure of BV was defined as: 1. discharge has returned to normal/physiologic, 2. the whiff test is negative for any amine "fishy" odor, 3. the saline wet mount is \<20% clue cells

    Time frame: 7-14 days after beginning treatment

  2. Cure of the VVC Component of Mixed Infection

    The percentage of participants with both BV and VVC who had clinical cure of VVC was compared between the combination therapy and the two single entity treatments.Clinical cure of VVC was defined as complete resolution of all signs and symptoms attributable to VVC

    Time frame: 7-14 days after beginning treatment

  3. Microbiologic and Mycologic Cure

    The percentage of participants with both microbiologic and mycologic cure was compared between the combination therapy and the two single entity treatments. Yeast cultures were performed and Gram stains of vaginal fluid were graded according to Nugent's criteria. Microbiologic cure requires normal Nugent gram stain score and mycologic cure requires negative yeast culture.

    Time frame: 7-14 days after beginning treatment

  4. Number of Participants Reporting Complete Resolution of Symptoms by Test of Cure Visit

    Subjects reported if symptoms completely resolved and the date of resolution. The percentage of participants reporting complete resolution of symptoms was compared between arms.

    Time frame: 7-14 days after beginning treatment

  5. Number of Participants With Treatment Emergent Adverse Events

    Adverse events were collected at study visits, from subject diaries and from spontaneous reports

    Time frame: Any time during study participation (up to 30 days)

07

Results

Posted Aug 4, 2020

Participant flow

Participant flow — Overall Study
MilestoneTerconazole Vaginal GelMetronidazole Vaginal GelTerconazole/Metronidazole Vaginal Gel
Started159159157
Completed838482
Not completed767575
Withdrew: Normal gram stain or neg yeast culture666467
Withdrew: Positive for std at baseline7117
Withdrew: Lost to follow-up301

Outcome measures

PrimaryClinical Cure of Mixed Infection (BV and VVC) as Assessed by the Investigator at the Test-of-cure Visit

The percentage of participants with clinical cure of both bacterial vaginosis (BV) AND vulvovaginal candidiasis (VVC) was compared between the combination therapy and the two single entity treatments. Clinical cure of BV is defined as: discharge has returned to normal/physiologic, negative whiff test, and saline wet mount is \<20% clue cells. Clinical cure of VVC is defined as resolution of all signs and symptoms attributable to vulvovaginal candidiasis

Time frame:
7-14 days after beginning treatment
Reported as:
Count of participants · Participants
Clinical Cure of Mixed Infection (BV and VVC) as Assessed by the Investigator at the Test-of-cure Visit
ParticipantsTerconazole Vaginal GelMetronidazole Vaginal GelTerconazole/Metronidazole Vaginal Gel
Clinical Cure of Mixed Infection (BV and VVC) as Assessed by the Investigator at the Test-of-cure Visit312943
Statistical analysis
  • Metronidazole Vaginal Gel vs Terconazole/Metronidazole Vaginal Gel · Chi-squared, Corrected · p = 0.030
  • Terconazole Vaginal Gel vs Terconazole/Metronidazole Vaginal Gel · Chi-squared, Corrected · p = 0.073
  • Metronidazole Vaginal Gel vs Terconazole/Metronidazole Vaginal Gel · Cochran-Mantel-Haenszel · p = 0.0204
  • Terconazole Vaginal Gel vs Terconazole/Metronidazole Vaginal Gel · Cochran-Mantel-Haenszel · p = 0.0493
SecondaryCure of the BV Component of Mixed Infection

The percentage of participants with both BV and VVC who had clinical cure of bacterial vaginosis (BV) was compared between the combination therapy and the two single entity treatments. Clinical cure of BV was defined as: 1. discharge has returned to normal/physiologic, 2. the whiff test is negative for any amine "fishy" odor, 3. the saline wet mount is \<20% clue cells

Time frame:
7-14 days after beginning treatment
Reported as:
Count of participants · Participants
Cure of the BV Component of Mixed Infection
ParticipantsTerconazole Vaginal GelMetronidazole Vaginal GelTerconazole/Metronidazole Vaginal Gel
Cure of the BV Component of Mixed Infection384654
Statistical analysis
  • Terconazole Vaginal Gel vs Terconazole/Metronidazole Vaginal Gel · Chi-squared, Corrected · p = 0.015
  • Metronidazole Vaginal Gel vs Terconazole/Metronidazole Vaginal Gel · Chi-squared, Corrected · p = 0.193
SecondaryCure of the VVC Component of Mixed Infection

The percentage of participants with both BV and VVC who had clinical cure of VVC was compared between the combination therapy and the two single entity treatments.Clinical cure of VVC was defined as complete resolution of all signs and symptoms attributable to VVC

Time frame:
7-14 days after beginning treatment
Reported as:
Count of participants · Participants
Cure of the VVC Component of Mixed Infection
ParticipantsTerconazole Vaginal GelMetronidazole Vaginal GelTerconazole/Metronidazole Vaginal Gel
Cure of the VVC Component of Mixed Infection523753
Statistical analysis
  • Metronidazole Vaginal Gel vs Terconazole/Metronidazole Vaginal Gel · Chi-squared, Corrected · p = 0.012
  • Terconazole Vaginal Gel vs Terconazole/Metronidazole Vaginal Gel · Chi-squared, Corrected · p = 0.918
SecondaryMicrobiologic and Mycologic Cure

The percentage of participants with both microbiologic and mycologic cure was compared between the combination therapy and the two single entity treatments. Yeast cultures were performed and Gram stains of vaginal fluid were graded according to Nugent's criteria. Microbiologic cure requires normal Nugent gram stain score and mycologic cure requires negative yeast culture.

Time frame:
7-14 days after beginning treatment
Reported as:
Count of participants · Participants
Microbiologic and Mycologic Cure
ParticipantsTerconazole Vaginal GelMetronidazole Vaginal GelTerconazole/Metronidazole Vaginal Gel
Microbiologic and Mycologic Cure19524
SecondaryNumber of Participants Reporting Complete Resolution of Symptoms by Test of Cure Visit

Subjects reported if symptoms completely resolved and the date of resolution. The percentage of participants reporting complete resolution of symptoms was compared between arms.

Time frame:
7-14 days after beginning treatment
Reported as:
Count of participants · Participants
Number of Participants Reporting Complete Resolution of Symptoms by Test of Cure Visit
ParticipantsTerconazole Vaginal GelMetronidazole Vaginal GelTerconazole/Metronidazole Vaginal Gel
Number of Participants Reporting Complete Resolution of Symptoms by Test of Cure Visit494449
SecondaryNumber of Participants With Treatment Emergent Adverse Events

Adverse events were collected at study visits, from subject diaries and from spontaneous reports

Time frame:
Any time during study participation (up to 30 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events
ParticipantsTerconazole Vaginal GelMetronidazole Vaginal GelTerconazole/Metronidazole Vaginal Gel
Number of Participants With Treatment Emergent Adverse Events444044

Adverse events

Collected over The safety population includes all participants randomized to treatment and administered at least one dose of study drug, and includes subjects who had a negative yeast culture and/or normal gram stain at the baseline visit. Adverse events were collected over the entire course of the study (up to 30 days after beginning treatment).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Terconazole Vaginal Gel0/149 (0%)1/149 (0.7%)5/149 (3.4%)
Metronidazole Vaginal Gel0/151 (0%)0/151 (0%)6/151 (4%)
Terconazole/Metronidazole Vaginal Gel0/154 (0%)0/154 (0%)8/154 (5.2%)
Most frequent serious events
Most frequent serious events
EventTerconazole Vaginal GelMetronidazole Vaginal GelTerconazole/Metronidazole Vaginal Gel
Diabetes mellitus inadequate controlMetabolism and nutrition disorders1/149——
Most frequent other events
Most frequent other events
EventTerconazole Vaginal GelMetronidazole Vaginal GelTerconazole/Metronidazole Vaginal Gel
Vulvovaginal burning sensationReproductive system and breast disorders5/1496/1518/154

Baseline characteristics

modified intent-to-treat (mITT) population includes all subjects randomized to treatment and administered at least one dose of study drug. In addition, subjects must have a Nugent score of 4 or more on Baseline visit Gram stain slide and a Baseline visit yeast culture positive for Candida species.

Age, Continuous
Age, Continuous(years)Terconazole Vaginal GelMetronidazole Vaginal GelTerconazole/Metronidazole Vaginal GelTotal
Mean31.5 ± 9.1731.0 ± 9.4332.6 ± 10.5731.7 ± 9.72
Sex: Female, Male
Sex: Female, Male(Participants)Terconazole Vaginal GelMetronidazole Vaginal GelTerconazole/Metronidazole Vaginal GelTotal
Female838482249
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Terconazole Vaginal GelMetronidazole Vaginal GelTerconazole/Metronidazole Vaginal GelTotal
Hispanic or Latino1515939
Not Hispanic or Latino686973210
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Terconazole Vaginal GelMetronidazole Vaginal GelTerconazole/Metronidazole Vaginal GelTotal
American Indian or Alaska Native1203
Asian0112
Native Hawaiian or Other Pacific Islander0011
Black or African American525450156
White30262884
More than one race0123
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Terconazole Vaginal GelMetronidazole Vaginal GelTerconazole/Metronidazole Vaginal GelTotal
United States838482249
08

Study locations

51 sites
  • Alabama Clinical Therapeutics
    Birmingham, Alabama 35205, United States
  • University of Alabama
    Birmingham, Alabama 35294, United States
  • Precision Trials, AZ
    Phoenix, Arizona 85032, United States
  • MomDoc Womens Health Research
    Scottsdale, Arizona 85251, United States
  • DelSol Research
    Tucson, Arizona 85710, United States
  • NEA Baptist Clinic
    Jonesboro, Arkansas 72401, United States
  • Gossmont Center for Clinical Research
    La Mesa, California 91942, United States
  • Genesis Center for Clinical Research
    San Diego, California 92103, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • Downtown Women's Health Care
    Denver, Colorado 80209, United States
  • Red Rocks Ob/Gyn
    Lakewood, Colorado 80228, United States
  • Women's Health CT Ob/Gyn
    Bridgeport, Connecticut 06606, United States
  • Precision Clinical Research
    Coral Springs, Florida 33065, United States
  • KO Clinical Research, LLC
    Fort Lauderdale, Florida 33316, United States
  • Segal Institute for Clinical Research
    North Miami, Florida 33161, United States
  • Discovery Clinical Research
    Plantation, Florida 33324, United States
  • Comprehensive Clinical Trials, LLC
    West Palm Beach, Florida 33409, United States
  • Georgia Regents University
    Augusta, Georgia 30912, United States
  • Atlanta North Gynecology
    Roswell, Georgia 30075, United States
  • Mount Vernon CLinical Research
    Sandy Springs, Georgia 30328, United States
  • Rosemark Womens Care Specialists
    Idaho Falls, Idaho 83404, United States
  • Women's Health Practice
    Champaign, Illinois 61802, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • Praetorian Pharmaceutical Research, LLC
    Marrero, Louisiana 70072, United States
  • Southern Clinical Research Associates
    Metairie, Louisiana 70001, United States
  • Women Under Study
    New Orleans, Louisiana 70125, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • Women's Healthcare Specialists, PC
    Kalamazoo, Michigan 49009, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Women's Clinic of Lincoln
    Lincoln, Nebraska 68510, United States
  • Legacy Women's Health
    Las Vegas, Nevada 89123, United States
  • R. Garn Mabey Jr., MD Gynecology
    Las Vegas, Nevada 89128, United States
  • Lawrence Ob/Gyn Clinical Research LLC
    Lawrenceville, New Jersey 08648, United States
  • Women's Health Research Center
    Plainsboro, New Jersey 08536, United States
  • Suffolk OB/GYN
    Port Jefferson, New York 11777, United States
  • East Carolina Women's Center
    New Bern, North Carolina 28562, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Radiant Research
    Columbus, Ohio 43212, United States
  • Complete Healthcare for Women
    Columbus, Ohio 43231, United States
  • Drexel University
    Philadelphia, Pennsylvania 19102, United States
  • Philapelphia Clinical Research, LLC
    Philadelphia, Pennsylvania 19114, United States
  • Magee-Womens Hospital of UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • Magnolia Ob/Gyn Research Center
    Myrtle Beach, South Carolina 29572, United States
  • James T. Martin, MD
    North Charleston, South Carolina 29406, United States
  • The Jackson Clinic
    Jackson, Tennessee 38305, United States
  • Discovery Clinical Trials
    Dallas, Texas 75231, United States
  • Signature Gyn Services
    Fort Worth, Texas 76104, United States
  • Texas Children's Hospital for Women
    Houston, Texas 77030, United States
  • TMC Life Research, Inc.
    Houston, Texas 77054, United States
  • Harborview Medical Center
    Seattle, Washington 98104, United States
  • Women's Clinical Research Center
    Seattle, Washington 98105, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of Jun 2018 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2020, 2 years 2 months after primary completion. A results delay was requested in Jun 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2014
First posted
Dec 4, 2014
Start
Jun 2015
Primary completionActual
Jun 2018
CompletionActual
Jun 2018
Results delay requested
Jun 26, 2018
Results first posted
Aug 4, 2020
Last update
Aug 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02308007
Lead sponsor
Curatek Pharmaceuticals, LLC
Responsible party
Sponsor
First posted
Dec 4, 2014
Start date
Jun 2015
Primary completion
Jun 2018
Completion
Jun 2018
Results posted
Aug 4, 2020
Last update
Aug 4, 2020

Study contacts

Robert J Borgman, Ph.D.
study director · Curatek Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metronidazole

Start the discussion